DOCSLIB.ORG

A Disaccharide That Inhibits Tumor Necrosis Factor a Is Formed from the Extracellular Matrix by the Enzyme Heparanase

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Disaccharide That Inhibits Tumor Necrosis Factor a Is Formed from the Extracellular Matrix by the Enzyme Heparanase Proc. Natl. Acad. Sci. USA Vol. 92, pp. 5037-5041, May 1995 Immunology A disaccharide that inhibits tumor necrosis factor a is formed from the extracellular matrix by the enzyme heparanase (cytokines/extracellular matrix/heparan sulfate/delayed-type hypersensitivity) OFER LIDER*, LioRA CAHALON*, DALiA GILAT*, RAMI HERSHKOVIZ*, DANIEL SIEGELt, RAANAN MARGALIT*, ODED SHOSEYOVt, and IRUN R. COHEN*t *Department of Cell Biology, The Weizmann Institute of Science, Rehovot 76100, Israel; and tThe Kennedy-Leigh Center for Horticultural Research, Faculty of Agriculture, The Hebrew University of Jerusalem, Rehovot 76100, Israel Communicated by Michael Sela, The Weizmann Institute of Science, Rehovot, Israel, January 11, 1995 (received for review December 1, 1994) ABSTRACT The activation of T cells by antigens or gram amounts of ECM disaccharide suppresses T-cell medi- mitogens leads to the secretion of cytokines and enzymes that ated reactivity in vivo. Incubation of T cells with the ECM shape the inflammatory response. Among these molecular disaccharide inhibits T-cell production of the active form of mediators of inflammation is a heparanase enzyme that tumor necrosis factor (TNF)-a, a major inflammatory cytokine. degrades the heparan sulfate scaffold of the extracellular matrix (ECM). Activated T cells use heparanase to penetrate the ECM and gain access to the tissues. We now report that MATERIALS AND METHODS among the breakdown products of the ECM generated by Heparanase. Mammalian heparanases have not yet been heparanase is a trisulfated disaccharide that can inhibit cloned; because T-cell heparanase was not available in quan- delayed-type hypersensitivity (DTH) in mice. This inhibition tity, we used heparanase obtained from human placentas. The ofT-cell mediated inflammation in vivo was associated with an heparanase enzyme was prepared and purified to >3.4 x inhibitory effect of the disaccharide on the production of 105-fold by ammonium sulfate precipitation followed by se- biologically active tumor necrosis factor a (TNF-a) by acti- quential chromatographies on carboxymethyl-, heparin-, and vated T cells in vitro; the trisulfated disaccharide did not affect Con A-Sepharose columns (RAD Chemicals, Ness Ziona, or T-cell viability responsiveness generally. Both the in vivo Israel) by modifying the technique of Oosta et at (7). The and in vitro effects of the disaccharide a manifested bell- specific activity of the heparanase was determined, as de- shaped dose-response curve. The inhibitory effects of the scribed, by its ability to release 35S04-labeled fragments of trisulfated disaccharide were lost if the sulfate groups were heparan sulfate from removed. Thus, the disaccharide, which may be a natural the ECM (3, 4). product of inflammation, can regulate the functional nature Preparation of ECM Disaccharide. ECM-coated plates of the response by the T cell to activation. Such a feedback were prepared from bovine corneal endothelial cells as de- control mechanism could enable the T cell to assess the extent scribed (5). Each ECM-coated plate was incubated for 48 h at of tissue degradation and adjust its behavior accordingly. 37°C with 20 ,ul of mammalian heparanase (0.5 mg/ml) in 1 ml of phosphate citrate buffer (18 mM citric acid/64 mM Na2HPO4/50 mM Some years ago, we reported that activated T cells secreted NaCl/1 mM CaCl2/1 mM dithiothreitol, pH heparanase, an enzyme that degrades the heparan-sulfate 6.2). The culture medium containing the ECM heparan sulfate component of the extracellular matrix (ECM; refS. 1 and 2). degradation products was then collected and applied to a The expression of heparanase by T cells, unlike that by tumor Sepharose 4B column (0.7 x 35 cm). The mobile phase was cells, was found to be tightly regulated by contact with specific phosphate citrate buffer at a flow rate of 5 ml/h. Fractions of antigen or mitogen. Naive T cells responded to activation by 1.6 ml were collected and monitored at 206 nm to detect synthesizing heparanase de novo but memory T cells were able oligosaccharides (Fig. 1A) or at 232 nm to detect unsaturated to release heparanase from preformed stores within minutes of disaccharides. Quantitation of the uronic acid containing contact with antigen (2). disaccharides was done by using the carbazole assay (8). The In addition to the positive induction of heparanase expres- lower molecular weight fractions, fractions 5 and 6, of the sion by T-cell activators, heparanase expression was also found Sepharose 4B peak were combined and freeze-dried, and the to be inhibitable by heparin (3-6). Heparin is very similar powder was resuspended in 10% of the initial volume. The chemically to heparan sulfate, the natural substrate of hepara- disaccharide was then isolated from the elution profile by using nase, and it was proposed that heparin, by occupying the HPLC gel-filtration chromatography followed by HPLC ion- binding site of the enzyme, may act as a competitive inhibitor exchange chromatography. Samples of 0.1 ml were injected of heparanase activity (3, 5, 6). However, we found that low into an HPLC column [Toyo Soda (Tokyo) TSK-Gel G3000 doses of heparin appeared to act directly on T cells to inhibit SW; 7.5 mm x 50 cm; and G2000 SW; 7.5 mm x 50 cm; in their release of heparanase (4, 5). Heparin is composed of series with a 7.5 mm x 10 cm guard column from Phenomenex different sulfated sugar molecules, and the saccharide moieties (Belmont, CA)]. The mobile phase was 0.5 M NaCl at a flow that inhibit T-cell heparanase release differ from those that rate of 1 ml/min. Fractions (1 ml) were collected and moni- inhibit blood coagulation (4). We reasoned that the T-cell tored at 206 and 232 nm. The column was calibrated with inhibitory molecules in heparin might actually mimic mole- heparin-oligosaccharide standards (Seikagaku Kogyo, Tokyo). cules produced by the action of heparanase on its natural The peak labeled pl in Fig. 1B, having the retention time of a substrate heparan sulfate. We report here the isolation of a disaccharide, was collected from nine identical runs. The trisulfated disaccharide generated by the action of heparanase substantially homogeneous fractions were combined and on the ECM (ECM disaccharide). Administration of nano- freeze-dried. The publication costs of this article were defrayed in part by page charge Abbreviations: DTH, delayed-type hypersensitivity; ECM, extracellu- payment. This article must therefore be hereby marked "advertisement" in lar matrix; TNF-a, tumor necrosis factor a; PHA, phytohemagglutinin. accordance with 18 U.S.C. §1734 solely to indicate this fact. *To whom reprint requests should be addressed. 5037 Downloaded by guest on September 29, 2021 5038 Immunology: Lider et al Proc. Nati Acad Sci. USA 92 (1995) A injected into an analytical Sax-HPLC column (4.6 x 250 mm; packed with Spherisorb; Phase Separation, Inc., Norwalk, CT; -F5 5-gm particle size). The column flow rate was 1.5 ml/min and an NaCl linear gradient program was employed as shown in Table 1. The column eluent was monitored at 206 nm (Fig. 1 C) and the peak labeled A23/4 was collected and quantified by the carbazole assay. To characterize the isolated disaccharide molecule, we compared its retention time to various known heparin disaccharide standards with different levels of sulfa- tion (Sigma) that were injected into the Sax-HPLC column under identical conditions. The retention time of these stan- dards indicated that the ECM disaccharide was probably trisulfated. A trisulfated disaccharide standard (a-A&UA-2S- 1--4-GlcNS, 6S; Sigma; H 9267) had a very similar retention time to that obtained for peakA23/4: 23.07 min and 23.10 min, Fraction no. respectively. We were able to isolate a radiolabeled trisulfated disaccharide when the heparanase was used to degrade an B ECM metabolically labeled with Na235SO4 (ref. 2; data not shown). This indicates that the isolated disaccharide did in fact originate from the ECM. 0.03 Fast atom bombardment-mass spectrometry (FAB-MS) of methylated, partially desulfated A23/4 was consistent with a molecular weight of about 530 for a methylated derivative. The 0.02 proton NMR spectrum of the trisulfated disaccharide was recorded in 2H20 at 500 MHz. Typical sugar signals were 9 (4 evident between 3 and 5.5 ppm. A doublet signal for the '11. anomeric proton was found at 5.39 ppm having a coupling 0.01 factor of 3 Hz, suggesting the presence of a glucosamine sugar unit in an a configuration. The chemical shift of the anomeric proton, together with what is believed to be the 13-glucuronide 0* specificity of placental heparanase, leads to the tentative conclusion that the ECM disaccharide has a glucosamine at the nonreducing end in an a configuration attached 1-4 to a -0.01 glucuronide acid residue at the reducing end. The complete 40 50 60 identification and the organic synthesis of the proposed mol- Retention time, min ecule will be published elsewhere. A desulfated disaccharide was obtained by incubating some 0.03 C of the disaccharide of peak A23/4 for 4 days at room tem- perature at pH 3.5. The nonsulfated disaccharide was isolated 0.026 A23/4 by its shorter retention time on the Sax-HPLC column, which was very similar to the retention time of a monosulfated 0.022- disaccharide standard (a-AUA-2S-[1-+4]-GlcNAc; Sigma; H 8767). 0.018- Delayed-Type Hypersensitivity (DTH) Assay. Groups of 10 A female inbred BALB/c mice (The Jackson Laboratory) were 0.014 sensitized on the shaved abdominal skin with 100 ,ul of 2% 0.01 oxazalone dissolved in acetone/olive oil [4:1 (vol/vol)] applied topically (5). DTH sensitivity was elicited 5 days later by 0.006 challenging the mice with 20 ,ul of 0.5% oxazalone in acetone/ olive oil, 10 ,ul administered topically to each side of the ear.
Load more

Recommended publications
  • Localization of Heparanase in Esophageal Cancer Cells: Respective Roles in Prognosis and Differentiation
    Laboratory Investigation (2004) 84, 1289–1304 & 2004 USCAP, Inc All rights reserved 0023-6837/04 $30.00 www.laboratoryinvestigation.org Localization of heparanase in esophageal cancer cells: respective roles in prognosis and differentiation Takaomi Ohkawa1, Yoshio Naomoto1, Munenori Takaoka1, Tetsuji Nobuhisa1, Kazuhiro Noma1, Takayuki Motoki1, Toshihiro Murata1, Hirokazu Uetsuka1, Masahiko Kobayashi1, Yasuhiro Shirakawa1, Tomoki Yamatsuji1, Nagahide Matsubara1, Junji Matsuoka1, Minoru Haisa1, Mehmet Gunduz2, Hidetsugu Tsujigiwa2, Hitoshi Nagatsuka2, Masao Hosokawa3, Motowo Nakajima4 and Noriaki Tanaka1 1Department of Gastroenterological Surgery, Transplant, and Surgical Oncology; 2Department of Oral Pathology and Medicine, Graduate School of Medicine and Dentistry, Okayama University, Okayama, Japan; 3Keiyukai Sapporo Hospital, Sapporo, Japan and 4Tsukuba Research Institute, Novartis Pharma KK Tsukuba, Japan In this study, we examined the distribution of heparanase protein in 75 esophageal squamous cell carcinomas by immunohistochemistry and analyzed the relationship between heparanase expression and clinicopatho- logical characteristics. In situ hybridization showed that the mRNA expression pattern of heparanase was similar to that of the protein, suggesting that increased expression of the heparanase protein at the invasive front was caused by an increase of heparanase mRNA in tumor cells. Heparanase expression correlated significantly with depth of tumor invasion, lymph node metastasis, tumor node metastasis (TNM) stage and lymphatic
    [Show full text]
  • Ultrasensitive Small Molecule Fluorogenic Probe for Human Heparanase
    bioRxiv preprint doi: https://doi.org/10.1101/2020.03.26.008730; this version posted March 29, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Ultrasensitive small molecule fluorogenic probe for human heparanase Jun Liu1, 2, Kelton A. Schleyer1, 2, Tyrel L. Bryan2, Changjian Xie2, Gustavo Seabra1, Yongmei Xu3, Arjun Kafle2, Chao Cui1, 2, Ying Wang2, Kunlun Yin2, Benjamin Fetrow2, Paul K. P. Henderson2, Peter Z. Fatland2, Jian Liu3, Chenglong Li1, Hua Guo2, and Lina Cui1, 2, * 1Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville, FL 32610, USA (Current) 2Department of Chemistry and Chemical Biology, University of New Mexico, Albuquerque, NM 87131, USA 3Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA *Correspondence should be addressed to L.C. E-mail: [email protected] Abstract Heparanase is a critical enzyme involved in the remodeling of the extracellular matrix (ECM), and its elevated expression has been linked with diseases such as cancer and inflammation. The detection of heparanase enzymatic activity holds tremendous value in the study of the cellular microenvironment, and search of molecular therapeutics targeting heparanase, however, assays developed for this enzyme so far have suffered prohibitive drawbacks. Here we present an ultrasensitive fluorogenic small-molecule probe for heparanase enzymatic activity. The probe exhibits a 756-fold fluorescence turn-on response in the presence of human heparanase, allowing one-step detection of heparanase activity in real-time with a picomolar detection limit.
    [Show full text]
  • Heparanase Is Required for Activation and Function of Macrophages
    Heparanase is required for activation and function of macrophages Lilach Gutter-Kapona, Dror Alishekevitzb, Yuval Shakedb, Jin-Ping Lic, Ami Aronheimd, Neta Ilana, and Israel Vlodavskya,1 aCancer and Vascular Biology Research Center, Bruce Rappaport Faculty of Medicine, Technion, Haifa 31096, Israel; bDepartment of Cell Biology and Cancer Science, Bruce Rappaport Faculty of Medicine, Technion, Haifa 31096, Israel; cDepartment of Medical Biochemistry and Microbiology, University of Uppsala, SE-751 05 Uppsala, Sweden; and dDepartment of Molecular Genetics, the Bruce Rappaport Faculty of Medicine, Technion, Haifa 31096, Israel Edited by Joseph Schlessinger, Yale University School of Medicine, New Haven, CT, and approved October 17, 2016 (received for review July 13, 2016) The emerging role of heparanase in tumor initiation, growth, The carcinoma microenvironment includes nontransformed metastasis, and chemoresistance is well recognized and is encouraging epithelial cells, fibroblasts, endothelial cells, and infiltrated immune the development of heparanase inhibitors as anticancer drugs. Unlike cells. Endothelial cells lining blood and lymph vessels are major the function of heparanase in cancer cells, very little attention has component of the tumor microenvironment, and antiangiogenesis been given to heparanase contributed by cells composing the tumor therapy, targeting vascular endothelial growth factor (VEGF) or microenvironment. Here we used a genetic approach and examined its receptor (VEGFR2), is implemented clinically (15). In addi- the behavior and function of macrophages isolated from wild-type tion, recent research has revealed the critical roles of inflam- (WT) and heparanase-knockout (Hpa-KO) mice. Hpa-KO macrophages matory responses in different stages of tumor development and express lower levels of cytokines (e.g., TNFα,IL1-β) and exhibit lower metastasis (16).
    [Show full text]
  • Trevigen Price List 2008 International.Indd
    BASEMENT MEMBRANE EXTRACT PRODUCTS AND SPECIALTY PROTEINS • CELL INVASION ASSAYS • DIRECTED IN VIVO ANGIOGENESIS ASSAYS • COMETASSAYTM • TREVIGEN PAR/PARP/PARG • PRODUCT FOCUS and price list 2008-2009MAY 2008 TACSTM IN SITU APOPTOSIS DETECTION KITS • 1.800.TREVIGEN • www.trevigen.com 2008 TREVIGEN PRODUCT FOCUS AND PRICE LIST Product Overviews BME Tools for 3D Culture Assays TACS™ Basement Membrane Extract Products and 3D Culture Cell Proliferation Assay (96 well) .......10 In Situ Apoptosis Detection Kits .....................18-23 Specialty Proteins ............................................2-5 3D Culture Cell Harvesting Kit ............................11 Annexin DIVAA™ PAR/PARP/PARG For monitoring apoptosis via flow cytometry ...24-25 Directed in vivo Angiogenesis Assays .................6-7 Kits, Reagents, Antibodies, and Enzymes .......12-14 Oxidative Stress Kits Cell Invasion/Migration Assays CometAssay™ ..................................................................26-27 Kits, Reagents, and Plates ................................8-9 Kits, Reagents, and Slides ............................15-17 Trevigen Product International Cell Assays ......................................25 Price List ..........................................28-38 Distributors ..............................39-40 Ordering Information • Please use product names and catalog numbers when ordering. Conditions Trevigen products are sold for Research Use Only. • Please provide your name, purchase order number, shipping address, billing address, and telephone number
    [Show full text]
  • Evidence Against a Role for Heparan Sulfate in Glomerular Permselectivity
    JASN Express. Published on February 14, 2007 as doi: 10.1681/ASN.2007010086 Editorial Breaking Down the Barrier: Evidence against a Role for Heparan Sulfate in Glomerular Permselectivity Scott J. Harvey and Jeffrey H. Miner Renal Division, Washington University School of Medicine, St. Louis, Missouri J Am Soc Nephrol 18: 672–674, 2007. doi: 10.1681/ASN.2007010086 he glomerular capillary wall is thought to function as Charge barrier dysfunction has long been touted as an un- both a size- and charge-selective barrier. The concept of derlying cause of human glomerular disease (10–12). This may T charge selectivity emerged from a series of now classic be brought about by decreased expression or undersulfation of studies that used tracers such as dextran, peroxidase, and fer- GBM-HSPG (13,14). Segmental or global loss of GBM-HS has ritin to evaluate the influence of molecular charge on glomer- been reported in human membranous nephritis, lupus nephri- ular filtration (1–5). The permeability of anionic derivatives of tis, minimal change disease, and diabetic nephropathy (13,15), each tracer was lower than their neutral counterparts of com- as well as in rat models of adriamycin and Heymann nephritis parable size, whereas the permeability of cationic forms was (16,17). The intensity of GBM labeling inversely correlates with enhanced. This led to the theory that the passage of endoge- severity of disease, which supports the theory that reductions nous circulating polyanions, notably albumin, would likewise in GBM-HS contribute directly to a loss of barrier function. be impeded by the “fixed” or intrinsic negative charge of the However, in a recent study, GBM-HS was reported to be nor- glomerular capillary wall.
    [Show full text]
  • Regulation and Function of Heparanase in the Heart
    Regulation and function of heparanase in the heart by FULONG WANG B.Sc., Southeast University, 2009 M.Sc., University of Chinese Academy of Sciences, 2013 A DISSERTATION SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY in THE FACULTY OF GRADUATE AND POSTDOCTORAL STUDIES (Pharmaceutical Sciences) THE UNIVERSITY OF BRITISH COLUMBIA (Vancouver) December 2018 © Fulong Wang, 2018 The following individuals certify that they have read, and recommend to the Faculty of Graduate and Postdoctoral Studies for acceptance, the dissertation entitled: Regulation and function of heparanase in the heart submitted Fulong Wang in partial fulfillment of the requirements by for the Doctor of Philosophy degree of in Pharmaceutical Sciences Examining Committee: Brian Rodrigues, Pharmaceutical Sciences Supervisor Dan Luciani, Faculty of Medicine Supervisory Committee Member Bruce Verchere, Faculty of Medicine Supervisory Committee Member Lucy Marzban University Examiner Angela Devlin University Examiner Additional Supervisory Committee Members: David Granville, Faculty of Medicine Supervisory Committee Member Corey Nislow, Pharmaceutical Sciences Supervisory Committee Member ii Abstract Enzymatically-active heparanase (HepA) has been implicated as an essential metabolic adaptation in the heart following diabetes. However, the regulation of the enzymatically- inactive heparanase (HepL) remain poorly understood. We hypothesized that in response to high glucose (HG) and secretion of HepL from the endothelial cell (EC), HepL uptake and function can protect the cardiomyocyte by modifying its cell death signature. HG promoted both HepL and HepA secretion from EC, with subsequent uptake of HepL into cardiomyocytes. This occurred through a low-density lipoprotein receptor-related protein 1 (LRP1) dependent mechanism, as LRP1 inhibition significantly reduced uptake.
    [Show full text]
  • Extracellular Matrix Degrading Enzymes at the Prostasome Surface
    Prostate Cancer and Prostatic Diseases (2005) 8, 344–348 & 2005 Nature Publishing Group All rights reserved 1365-7852/05 $30.00 www.nature.com/pcan Extracellular matrix degrading enzymes at the prostasome surface I Bellezza1, MC Aisa2, R Palazzo1, E Costanzi1, E Mearini3 & A Minelli1* 1Dipartimento Medicina Sperimentale Scienze Biochimiche, Sezione Biochimica Cellulare, Perugia, Italy; 2Dipartimento Medicina Interna, Sezione Biochimica Applicata Scienze Nutrizionali, Perugia, Italy; and 3Diparimento Specialita` Chirurgiche, Sezione di Urologia, Universita` di Perugia, Perugia, Italia Prostasomes, prostatic secretory vesicles found in human ejaculates, were analyzed to verify the existence at their surfaces of enzymes involved in the degradation of the extracellular matrix. Findings were compared with those of prostasomes isolated from two human adenocarcinoma cell lines that reflect clinical features and molecular pathways of androgen-insensitive and hormone-responsive prostate cancer. Our aim was to determine whether neoplastic transformation is accompanied by changes of glycosidase and protease activities. Our results show that decreases of dipeptidyl peptidase IV and increases of urokinase plasminogen activator and cathepsin B are consistent with the clinical features of the cell lines, whereas increases of glycosidase activities seem to be of scarce biological significance. Prostate Cancer and Prostatic Diseases (2005) 8, 344–348. doi:10.1038/sj.pcan.4500828; published online 30 August 2005 Keywords: PC3; LNCaP; glycosidases; proteases Introduction istics and the presence of saturated and monounsatu- rated fatty acids make the prostasome membrane highly The human prostate gland has a remarkably high ordered and rigid.1 A proteomic analysis has shown the incidence of neoplastic disease and prostate cancer is existence at the prostasome surface of at least 139 one of the most commonly detected male cancers that proteins including enzymes (35%), transport/structural result in a high incidence of mortality.
    [Show full text]
  • Degradation of Heparan Sulfate in the Subendothelial Extracellular Matrix by a Readily Released Heparanase from Human Neutrophils
    Degradation of heparan sulfate in the subendothelial extracellular matrix by a readily released heparanase from human neutrophils. Possible role in invasion through basement membranes. Y Matzner, … , Z Fuks, I Vlodavsky J Clin Invest. 1985;76(4):1306-1313. https://doi.org/10.1172/JCI112104. Research Article Freshly isolated human neutrophils were investigated for their ability to degrade heparan sulfate proteoglycans in the subendothelial extracellular matrix (ECM) produced by cultured corneal and vascular endothelial cells. The ECM was metabolically labeled with Na2(35S)O4 and labeled degradation products were analyzed by gel filtration over Sepharose 6B. More than 90% of the released radioactivity consisted of heparan sulfate fragments 5-6 times smaller than intact heparan sulfate side chains released from the ECM by either papain or alkaline borohydride. These fragments were sensitive to deamination with nitrous acid and were not produced in the presence of either heparin or serine protease inhibitors. In contrast, degradation of soluble high molecular weight heparan sulfate proteoglycan, which was first released from the ECM, was inhibited by heparin but there was no effect of protease inhibitors. These results indicate that interaction of human neutrophils with the subendothelial ECM is associated with degradation of its heparan sulfate by means of a specific, newly identified, heparanase activity and that this degradation is facilitated to a large extent by serine proteases. The neutrophil heparanase was readily and preferentially
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,689,046 B2 Mayall Et Al
    USOO9689046B2 (12) United States Patent (10) Patent No.: US 9,689,046 B2 Mayall et al. (45) Date of Patent: Jun. 27, 2017 (54) SYSTEM AND METHODS FOR THE FOREIGN PATENT DOCUMENTS DETECTION OF MULTIPLE CHEMICAL WO O125472 A1 4/2001 COMPOUNDS WO O169245 A2 9, 2001 (71) Applicants: Robert Matthew Mayall, Calgary (CA); Emily Candice Hicks, Calgary OTHER PUBLICATIONS (CA); Margaret Mary-Flora Bebeselea, A. et al., “Electrochemical Degradation and Determina Renaud-Young, Calgary (CA); David tion of 4-Nitrophenol Using Multiple Pulsed Amperometry at Christopher Lloyd, Calgary (CA); Lisa Graphite Based Electrodes', Chem. Bull. “Politehnica” Univ. Kara Oberding, Calgary (CA); Iain (Timisoara), vol. 53(67), 1-2, 2008. Fraser Scotney George, Calgary (CA) Ben-Yoav. H. et al., “A whole cell electrochemical biosensor for water genotoxicity bio-detection”. Electrochimica Acta, 2009, 54(25), 6113-6118. (72) Inventors: Robert Matthew Mayall, Calgary Biran, I. et al., “On-line monitoring of gene expression'. Microbi (CA); Emily Candice Hicks, Calgary ology (Reading, England), 1999, 145 (Pt 8), 2129-2133. (CA); Margaret Mary-Flora Da Silva, P.S. et al., “Electrochemical Behavior of Hydroquinone Renaud-Young, Calgary (CA); David and Catechol at a Silsesquioxane-Modified Carbon Paste Elec trode'. J. Braz. Chem. Soc., vol. 24, No. 4, 695-699, 2013. Christopher Lloyd, Calgary (CA); Lisa Enache, T. A. & Oliveira-Brett, A. M., "Phenol and Para-Substituted Kara Oberding, Calgary (CA); Iain Phenols Electrochemical Oxidation Pathways”, Journal of Fraser Scotney George, Calgary (CA) Electroanalytical Chemistry, 2011, 1-35. Etesami, M. et al., “Electrooxidation of hydroquinone on simply prepared Au-Pt bimetallic nanoparticles'. Science China, Chem (73) Assignee: FREDSENSE TECHNOLOGIES istry, vol.
    [Show full text]
  • 1994 De Vouge MW, Yamazaki A, Bennett SAL, Chen JH, Shwed PS
    Int. J. Cancer: 56,286-294 (1994) Publication of the International Union Against Cancer Publication de I Union Internattonale Contre le Cancer 0 1994 Wiley-Liss, Inc. a' IMMUNOSELECTION OF GRP94/ENDOPLASMIN FROM A KNRK CELL-SPECIFIC Xgt 11 LIBRARY USING ANTIBODIES DIRECTED AGAINST A PUTATIVE HEPARANASE AMINO-TERMINAL PEPTIDE Michael W. DE VOUGE',Amy YAMAZAKI~,Steffany A.L. BENNETT',Jia-Hua CHEN'4, Philip S. SHWED'2, Chantal COUTURE' and H. Chaim BIRNBOIM1,3 'Ottawa Regional Cancer Centre and University of Ottawa, 501 Smyth Road, Ottawa, Ontario, KlH 8L6, Canada. Induction of an invasive phenotype by metastatic tumour cells Enhanced release of HS fragments from Na2[35S04]-labeled results in part from inappropriate expression of extracellular extracellular matrix was initially correlated with metastatic matrix-degradingenzymes normally involved in embryonic mor- potential in cellular extracts, but not in conditioned media, of phogenesis, tissue remodelling, angiogenesis and wound heal- B16 murine melanoma clones (Nakajima et al., 1983). Analyses ing. Such enzymes include endoglycosidases that degrade hepa- of substrate specificity, and examination of reducing termini of ran sulfate (HS) in endothelial basement membrane, as well as better characterized proteases. Heparanase, an endo-P-D- HS fragments led to the characterization of heparanase as an glucuronidase initially detected in B I6 melanoma cells, has endo-P-D-glucuronidase that is inhibited by heparin (Na- been described as a M, 96 000 glycoprotein with pl of 5.2, and kajima et al.,
    [Show full text]
  • Acid Phosphatase 5 Is Responsible for Removing the Mannose 6-Phosphate Recognition Marker from Lysosomal Proteins
    Acid phosphatase 5 is responsible for removing the mannose 6-phosphate recognition marker from lysosomal proteins Pengling Suna, David E. Sleata, Miche` le Lecocqb, Alison R. Haymanc, Michel Jadotb, and Peter Lobela,1 aCenter for Advanced Biotechnology and Medicine and Department of Pharmacology, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, Piscataway, NJ 08854; bLaboratoire de Chimie Physiologique, Unite´de Recherche en Physiologie Mole´culaire, Faculte´s Universitaires Notre-Dame de la Paix, 61 rue de Bruxelles, 5000-Namur, Belgium; and cSchool of Clinical Veterinary Science, University of Bristol, Bristol BS40 5DU, UK Edited by Stuart A. Kornfeld, Washington University School of Medicine, St. Louis, MO, and approved September 12, 2008 (received for review July 31, 2008) Most newly synthesized proteins destined for the lysosome reach Golgi to repeat the process or to the plasma membrane. At the this location via a specific intracellular pathway. In the Golgi, a latter location, the CI-MPR can function in the endocytosis and phosphotransferase specifically labels lysosomal proteins with lysosomal targeting of extracellular Man-6-P glycoproteins. mannose 6-phosphate (Man-6-P). This modification is recognized Early studies indicated that Man-6 phosphorylation was a by receptors that target the lysosomal proteins to the lysosome transient modification of lysosomal proteins that was removed where, in most cell types, the Man-6-P recognition marker is rapidly with a half-life of 1.4 h in mouse lymphoma cells (3) and also removed. Despite extensive characterization of this pathway, the rapidly removed in CHO cells (4). The exact site of dephos- enzyme responsible for the removal of the targeting modification phorylation is not clear, and there is evidence suggesting that it has remained elusive.
    [Show full text]
  • In Vivo Fragmentation of Heparan Sulfate by Heparanase Overexpression Renders Mice Resistant to Amyloid Protein a Amyloidosis
    In vivo fragmentation of heparan sulfate by heparanase overexpression renders mice resistant to amyloid protein A amyloidosis Jin-Ping Li*†, Martha L. Escobar Galvis*‡, Feng Gong*‡§, Xiao Zhang¶, Eyal Zchariaʈ, Shula Metzger**, Israel Vlodavsky††, Robert Kisilevsky‡‡, and Ulf Lindahl* *Department of Medical Biochemistry and Microbiology, Biomedical Center, Uppsala University, Box 582, SE-751 23 Uppsala, Sweden; ¶Department of Public Health and Caring Science, Division of Molecular Geriatrics, Rudbeck Laboratory, Uppsala University, Box 609, SE-751 25 Uppsala, Sweden; Departments of ʈOncology and **Medicine, Hadassah-Hebrew University Medical Center, Jerusalem 91120, Israel; ††Cancer and Vascular Biology Research Center, The Bruce Rappaport Faculty of Medicine, Technion, Haifa 31096, Israel; and ‡‡Department of Pathology and Molecular Medicine, Queen’s University, Kingston, ON, Canada K7L 3N6 Communicated by D. Carleton Gajdusek, Centre National de la Recherche Scientifique, Gif-sur-Yvette, France, March 21, 2005 (received for review December 22, 2004) Amyloid diseases encompass >20 medical disorders that include The results demonstrate that overexpression of heparanase, amyloid protein A (AA) amyloidosis, Alzheimer’s disease, and type resulting in fragmentation of HS chains, affords protection 2 diabetes. A common feature of these conditions is the selective against amyloidosis. organ deposition of disease-specific fibrillar proteins, along with the sulfated glycosaminoglycan, heparan sulfate. We have gener- Materials and Methods ated transgenic mice that overexpress human heparanase and Animals and Amyloid Induction. The homozygous mouse strain have tested their susceptibility to amyloid induction. Drastic short- overexpressing human heparanase (hpa-tg) and the respective ening of heparan sulfate chains was observed in heparanase- control (ctr) mice (C57BL background) were generated as overproducing organs, such as liver and kidney.
    [Show full text]